|
gptkbp:instanceOf
|
gptkb:public_company
|
|
gptkbp:CEO
|
gptkb:Yvonne_Greenstreet
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:CUSIP
|
02043Q107
|
|
gptkbp:focus
|
RNA interference therapeutics
|
|
gptkbp:foundedYear
|
2002
|
|
gptkbp:founder
|
gptkb:David_Bartel
gptkb:Phillip_Sharp
gptkb:John_Maraganore
gptkb:Paul_Schimmel
gptkb:Thomas_Tuschl
gptkb:Phil_Zamore
|
|
gptkbp:hasCompany
|
gptkb:Alnylam_Pharmaceuticals,_Inc.
|
|
gptkbp:headquartersLocation
|
gptkb:Cambridge,_Massachusetts,_United_States
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:ISIN
|
US02043Q1076
|
|
gptkbp:listedOn
|
gptkb:NASDAQ
|
|
gptkbp:marketCap
|
multi-billion USD (varies)
|
|
gptkbp:notableProduct
|
gptkb:AMVUTTRA
gptkb:GIVLAARI
gptkb:ONPATTRO
gptkb:OXLUMO
|
|
gptkbp:numberOfEmployees
|
~2000
|
|
gptkbp:stockSymbol
|
gptkb:ALNY
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ:_ALNY
|
|
gptkbp:website
|
https://www.alnylam.com/
|
|
gptkbp:bfsParent
|
gptkb:Alnylam_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
NASDAQ: ALNY
|